ABSTRACT
Elevated levels of combustion-derived particulate matter (CDPM) are a risk factor for the development of lung diseases such as asthma. Studies have shown that CDPM exacerbates asthma, inducing acute lung dysfunction and inflammation; however, the impact of CDPM exposure on early immunological responses to allergens remains unclear. To determine the effects of early-life CDPM exposure on allergic asthma development in infants, we exposed infant mice to CDPM and then induced a mouse model of asthma using house dust mite (HDM) allergen. Mice exposed to CDPM+HDM failed to develop a typical asthma phenotype including airway hyper-responsiveness, T-helper type 2 (Th2) inflammation, Muc5ac expression, eosinophilia, and HDM-specific immunoglobulin (Ig) compared with HDM-exposed mice. Although HDM-specific IgE was attenuated, total IgE was twofold higher in CDPM+HDM mice compared with HDM mice. We further demonstrate that CDPM exposure during early life induced an immunosuppressive environment in the lung, concurrent with increases in tolerogenic dendritic cells and regulatory T cells, resulting in the suppression of Th2 responses. Despite having early immunosuppression, these mice develop severe allergic inflammation when challenged with allergen as adults. These findings demonstrate a mechanism whereby CDPM exposure modulates adaptive immunity, inducing specific antigen tolerance while amplifying total IgE, and leading to a predisposition to develop asthma upon rechallenge later in life.
Subject(s)
Environmental Exposure/adverse effects , Lung/immunology , Particulate Matter/adverse effects , Adoptive Transfer , Allergens/immunology , Animals , Animals, Newborn , Antigens/immunology , Asthma/genetics , Asthma/immunology , Asthma/metabolism , Asthma/pathology , Dendritic Cells/immunology , Disease Models, Animal , Immunosuppression Therapy , Lung/metabolism , Mice , Mucus/metabolism , Respiratory Hypersensitivity/genetics , Respiratory Hypersensitivity/immunology , Respiratory Hypersensitivity/metabolism , Respiratory Hypersensitivity/pathology , T-Lymphocytes, Regulatory/immunology , Th2 Cells/immunologyABSTRACT
Studies on the development of supported iron oxide catalysts for PCDD/F decomposition using 2-monochlorophenol as a surrogate test compound are presented. Iron oxide catalysts supported on titania were prepared by two methods: impregnation and the sol-gel method. The latter preparation method resulted in better dispersion of iron oxide on the surface and the formation of gamma-Fe2O3. This is in contrast to the impregnated samples where alpha-Fe2O3 crystallites were formed. Formation of gamma-Fe2O3 resulted in improved reducibility of the active phase that favorably affected the catalytic oxidation properties of the catalyst, i.e., the light-off curves for the sol-gel samples were shifted toward lower temperature. Addition of calcium oxide to iron oxide catalyst further improved the performance of the system through stabilization and increase in the concentration of gamma-Fe2O3 in the sol-gel prepared samples. Addition of calcium oxide has a dual effect on the performance of the catalyst. First, it creates oxygen vacancies in the reduction-resistant Fe2O3 octahedral structures, thereby improving the reducibility of the active phase. Second, iron oxide can transform during decomposition of chlorinated hydrocarbons into iron chloride. Calcium oxide improved the chlorine transfer from the surface iron oxide species, thereby providing a relatively fresh surface for further catalytic oxidation. Comparison of TPR profiles with the position of light-off curves in 2-monochlorophenol decomposition led to the conclusion that Fe3O4 species are the active phase under conditions that facilitate redox cycling between Fe3+ and Fe2+ ions.
